Igor Shafarevich

Igor Shafarevich

Auto-generated profile, based on publicly available information

Igor Shafarevich

Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2019 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
JMJohannes De Munter
Johannes De Munter
ISIgor Shafarevich
Igor Shafarevich
ALAlexei Liundup
Alexei Liundup
DPDmitrii Pavlov
Dmitrii Pavlov
EWErik Ch Wolters
Erik Ch Wolters
TSTatyana Strekalova
Tatyana Strekalova
Aims: Mutations in DNA/RNA‐binding factor (fused‐in‐sarcoma) FUS and superoxide dismutase‐1 (SOD‐1) cause amyotrophic lateral sclerosis (ALS). They were reproduced in SOD‐1‐G93A (SOD‐1) and new FUS[1‐359]‐transgenic (FUS‐tg) mice, where inflammation contributes to disease progression. The effects of standard disease therapy and anti‐inflammatory treatments were investigated using these mutants.Methods: FUS‐tg mice or controls received either vehicle, or standard ALS treatment riluzole (8 mg/kg/day), or anti‐inflammatory drug a selective blocker of cyclooxygenase‐2 celecoxib (30 mg/kg/day) for six weeks, or a single intracerebroventricular (i.c.v.) infusion of Neuro‐Cells (a preparation of 1.39 × 106mesenchymal and hemopoietic human stem cells, containing 5 × 105of CD34+cells), which showed anti‐inflammatory properties. SOD‐1 mice received i.c.v.‐administration of Neuro‐Cells or vehicle.Results: All FUS‐tg‐treated animals displayed less marked reductions in weight gain, food/water intake, and motor deficits than FUS‐tg‐vehicle‐treated mice. Neuro‐Cell‐treated mutants had reduced muscle atrophy and lumbar motor neuron degeneration. This group but not celecoxib‐FUS‐tg‐treated mice had ameliorated motor performance and lumbar expression of microglial activation marker, ionized calcium‐binding adapter molecule‐1 (Iba‐1), and glycogen‐synthase‐kinase‐3ß (GSK‐3ß). The Neuro‐Cells‐treated‐SOD‐1 mice showed better motor functions than vehicle‐treated‐SOD‐1 group.Conclusion: The neuropathology in FUS‐tg mice is sensitive to standard ALS treatments and Neuro‐Cells infusion. The latter improves motor outcomes in two ALS models possibly by suppressing microglial activation.

17 April 2020 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
JMJohannes De Munter
Johannes De Munter
ISIgor Shafarevich
Igor Shafarevich
ALAlexei Liundup
Alexei Liundup
DPDmitrii Pavlov
Dmitrii Pavlov
EWErik Ch Wolters
Erik Ch Wolters
TSTatyana Strekalova
Tatyana Strekalova
The inside front cover image is based on the Original Article Neuro‐Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice by Johannes P.J.M. de Munter et al., https://doi.org/10.1111/cns.13280.